Intermolecular, Inc.

If you purchased Intermolecular, Inc. securities and would like to join the action, please click "Join This Class Action" below.

INTERMOLECULAR (IMI) MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF INTERMOLECULAR, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – IMI

May 6, 2019.

New York, New York—Halper Sadeh LLP, a global investor rights law firm, announces it is investigating whether the sale of Intermolecular, Inc. (“Intermolecular” or the “Company”) (NASDAQ: IMI) to a wholly owned subsidiary of Merck KGaA (“Merck”) is fair to Intermolecular shareholders.

The investigation concerns whether Intermolecular and its Board of Directors violated the federal securities laws and/or their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Intermolecular shareholders; (2) determine whether Merck is underpaying for Intermolecular; and (3) disclose all material information necessary for Intermolecular shareholders to adequately assess and value the merger consideration.

On behalf of Intermolecular shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Join This Class Action

Scroll to Top